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Two other articles in this issue give views on the current status of
chemotherapy for advanced ovarian cancer. The consensus state-
ment (Adams et al 1998) makes it clear that many cancer physi-
cians consider the treatment ofchoice to be a paclitaxel-platinum
combination. The second, a review from the MRC's Cancer Trials
Office (Sandercock et al, 1998) analyses the issues surrounding
the various trials and attempts to explain all of the available data.
Two trials have shown that, beyond any reasonable doubt, pacli-
taxel-cisplatin is superior to cyclophosphamide-cisplatin.
However, pre-paclitaxel at least four regimens were considered
broadly equivalent in efficacy: single-agent cisplatin, single-agent
carboplatin, cisplatin-cyclophosphamide and cyclophosphamide-
doxorubicin-cisplatin (CAP). With paclitaxel now firmly estab-
lished, it seems unlikely that all such combinations will formally
be tested, and decisions may have to be made on indirect compar-
isons. In many countries, these results have led to paclitaxel-
cisplatin replacing cyclophosphamide-cisplatin as the routine
standard of care. In the UK, the most widely used regimen was
single-agent carboplatin, but as yet there are no results from trials
comparing this with carboplatin-paclitaxel. When ICON3 reports
(early in 1999), this will give firm evidence on which to base such
decisions but until then clinicians must decide on the optimal treat-
ment. There are trials showing broadly equivalent results from
paclitaxel-cisplatin and paclitaxel-carboplatin (Sandercock et al,
1998) and, thus, there is indirect evidence to support the use of
either combination, with the latter probably being less toxic and
certainly more convenient. However, where potential differences
are small, there is the possibility for significant overall differences
to be lost in such indirect comparisons. In addition, there is one
trial that appears to contradict this clear story. As both papers point
out, this appears to show that single-agent cisplatin (at a slightly
higher dose than when used with cyclophosphamide) is as effec-
tive as paclitaxel-cisplatin. This finding seems unlikely to be due
to chance but, as Sandercock et al (1998) explain in great detail,
there is no other clear explanation that would be consistent with all
the facts. A popular explanation is 'rescue' of cisplatin failures
with early paclitaxel-containing regimens - although this is
possible there may be other explanations (Sandercock et al, 1998).
What then is the current best treatment for advanced ovarian
cancer? It seems certain to be paclitaxel-platinum combination,
but there remain key questions that require more data. Particularly
important remaining issues are the true size of the benefit from
such treatment, the groups of patients who benefit and the advan-
tages in terms of quality of life, as the treatment is certainly more
toxic than the widely used single-agent carboplatin. The initial
trials were small, the confidence limits on increased survival large
and the trials too small to allow subgroup analysis. Clearly more
data would be desirable, but there may be little forthcoming as
some trials have been stopped early (GOG 114; Sandercock et al,
1998). Others, such as ICON3, although large and covering a wide
range of patients, and thus of great potential value in answering
these questions, may still suffer difficulties in interpretation. For
example, since paclitaxel was available for the whole duration of
the trial and is widely used for relapse (contrasting with the initial
reports where little paclitaxel was given on relapse), problems
comparable to the potential confounding effects ofearly crossover
seen in GOG132 (Sandercock et al, 1998) may be seen - we must
await the full reporting ofdata from the trial.
Such controversies make it hard for patients to be sure that they
are receiving the best treatment. Certainly, these debates are not
new, and in ovarian cancer similar uncertainties over the benefits
of cisplatin compared with simple alkylator therapy were
discussed some 20 years ago. For the future, the only way to mini-
mize such issues is to ensure that new drugs are fully evaluated
quickly and efficiently. Drugs that appear to be important
advances in cancer treatment are all too rare and to make sure that
patients receive the best treatment without wasting resources on
inappropriate treatments requires timely information from large-
scale trials. The major financial investment required to develop
new drugs means that their cost is likely to remain high, and this
adds to the importance of ascertaining their appropriate use.
Importantly, there is often a long gap between obtaining data
showing clinical benefit for licensing purposes and evaluation of
the ultimate role of a drug in therapy. Thus, the pharmaceutical
industry is unlikely to provide full funding for the whole process.
Those are important global issues, but in the UK there are
specific problems. It is proposed that the NHS, through the new
National Institute for Clinical Excellence (NICE), will recommend
best clinical practice - clearly this can only be based on appro-
priate evidence. Likewise, the MRC and other research organiza-
tions seek to undertake trials to provide such evidence.
Historically, the development of chemotherapy for cancer has an
enviable record ofprogress through clinical trials, but in the 'New
NHS' there are difficulties in funding such clearly vital research.
For example, when ICON3 was launched there were delays due to
difficulties with funding. The results of ICON3 may yet prove to
be of enormous value but could have been available significantly
earlier ifthe process offunding trials had been simpler. There was
no shortage ofclinicians wishing to enter patients into ICON3, but
some centres were not able to contribute patients because local
purchasers refused to fund drug costs for the trial. In many more
centres the bureaucracy concerned with obtaining funding
approval led to delays. Is there a better way of funding such trials
in the future? Encouraging and facilitating entry into such trials is
a major objective of the NHS R&D exercise, yet the funding is
given by a circuitous route which does not guarantee the money
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will go into this type of activity. Surely the simplest way is for
funding to be applied directly to provide/reimburse drug costs and
also provide support for data management/research nurses for
those trials, just as is the case with commercially sponsored trials.
Such a system would speed the uptake of such trials and ensure
that support goes directly to those centres that take part in such
research. This would only serve to encourage recruitment to the
benefit of all concerned.
Once such new treatments are established their continued
funding must be allotted from central government resources to
facilitate equal access for all. Without this there will continue to be
the wide variation in practice seen throughout the UK today.
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